This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cherry, J. D.
Right arrow Articles by Christenson, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cherry, J. D.
Right arrow Articles by Christenson, P.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 102 No. 4 October 1998, pp. 909-912

The Effect of Investigator Compliance (Observer Bias) on Calculated Efficacy in a Pertussis Vaccine Trial

Received Jan 22, 1998; accepted Mar 19, 1998.

James D. Cherry*, Ulrich HeiningerDagger , Klemens StehrDagger , and Peter Christenson*

From the * Department of Pediatrics and the University of California, Los Angeles Center for Vaccine Research, University of California, Los Angeles School of Medicine, Los Angeles, California; and the Dagger  Klinik mit Poliklinik für Kinder und Jugendliche der Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Background.  In the course of a large pertussis vaccine efficacy trial we realized that investigator compliance could have a major impact on calculated vaccine efficacy.

Design.  In our pertussis vaccine efficacy trial, the study investigators were to monitor illness in study families by telephone every 2 weeks. If a cough illness of >= 7 days duration was noted, the study child was to be evaluated. If the cough illness persisted for >= 14 days, the child was to be referred to a central investigator. For this report we analyzed study physician evaluation rates and rates of referral to the central investigators. Physician practices were separated into three compliance categories: high, intermediate, and low. We analyzed vaccine efficacy of an acellular pertussis component DTP vaccine (DTaP) and a whole cell pertussis component DTP vaccine (DTP) by compliance category. Bordetella pertussis infection was documented by culture of the organism in the study child or in a household contact or by a significant antibody response to pertussis toxin determined by enzyme-linked immunosorbent assay.

Results.  Using a clinical case definition that included both mild and typical pertussis (cough illness >= 7 days duration) efficacy of DTaP vaccine was 40% (95% confidence interval [CI] = -3-65) in the high compliance category and 78% (95% CI = 65-86) and 75% (95% CI = 53-87) in the intermediate and low compliance groups, respectively. Similar, but less marked, differences in efficacy were noted with DTP vaccine recipients. Using a clinical case definition that required >= 21 days of cough with paroxysms, whoop, or vomiting (typical pertussis) the efficacy of DTaP vaccine was 69% (95% CI = 41-83) in the high compliance category and 86% (95% CI = 76-92) and 84% (95% CI = 64-93) in the intermediate and low compliance groups, respectively. In contrast, the efficacy of DTP vaccine did not vary by compliance category using this case definition. The attack rate in children vaccinated with diphtheria and tetanus toxoids vaccine (DT) was twofold less in low compliance physician practices when compared with the rates in high and intermediate groups. The DT/DTaP and DT/DTP fold-change differences were less in the high compliance group compared with the intermediate and low compliance groups.

Conclusions.  Our data suggest that observer compliance (observer bias), can significantly inflate calculated vaccine efficacy. It is likely that all recently completed efficacy trials have been effected by this type of observer bias and all vaccines have considerably less efficacy against mild disease than published data suggest.  Key words:  observer bias, vaccine efficacy, acellular pertussis vaccine, whole cell pertussis vaccine, investigation compliance.




This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
S. Mattoo and J. D. Cherry
Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies
Clin. Microbiol. Rev., April 1, 2005; 18(2): 326 - 382.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. G. Liese, B. H. Belohradsky, A. M. Walker;, J. D. Cherry, and P. Olin
The Science and Fiction of Pertussis Vaccines
Pediatrics, March 1, 2001; 107(3): 611 - 612.
[Full Text]

Home page
 PediatricsHome page
U. Heininger, G. Schmidt-Schläpfer, J. D. Cherry, and K. Stehr
Clinical Validation of a Polymerase Chain Reaction Assay for the Diagnosis of Pertussis by Comparison With Serology, Culture, and Symptoms During a Large Pertussis Vaccine Efficacy Trial
Pediatrics, March 1, 2000; 105(3): 31e - 31.
[Abstract] [Full Text]

Home page
 PediatricsHome page
J. D. Cherry and P. Olin
The Science and Fiction of Pertussis Vaccines
Pediatrics, December 1, 1999; 104(6): 1381 - 1383.
[Full Text]

Home page
 PediatricsHome page
S. Salmaso, A. E. Tozzi, M. L. C. d. Atti;, and J. D. Cherry
Observer Bias in Acellular Pertussis Vaccine Trials
Pediatrics, October 1, 1999; 104(4): 997 - 997.
[Full Text]

Home page
 PediatricsHome page
C. H. W. von Konig, H. J. Schmitt, and A. Neiss
Observer Bias in Acellular Pertussis Vaccine Trials
Pediatrics, September 1, 1999; 104 (3): 577 - 578.
[Full Text] [PDF]